Abstract Number: 2558 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)
Background/Purpose: C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained…Abstract Number: 1616 • 2018 ACR/ARHP Annual Meeting
Region-Specific Differences in Clinical Presentation of Patients with Axial Spondyloarthritis – Results from a Large Multinational Cohort Study
Background/Purpose: There is limited evidence on the phenotypic characteristics of axial spondyloarthritis (axSpA) patients (pts) in various geographic regions around the world. This analysis aimed…Abstract Number: 2569 • 2018 ACR/ARHP Annual Meeting
Association of Enthesitis with Achievement of Normal Quality of Life and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Adalimumab
Background/Purpose: Enthesitis, a key pathology in non-radiographic axial spondyloarthritis (nr-axSpA), has been difficult to treat with conventional therapies and may take longer to resolve than…Abstract Number: 1503 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Axial Spondyloarthritis in Israel
Background/Purpose: The concept of axial Spondyloarthritis (SpA) as defined by the ASAS criteria is relatively new. While the prevalence of Ankylosing spondylitis is around 0.5%,…Abstract Number: 2803 • 2017 ACR/ARHP Annual Meeting
Predictors of Remission Maintenance up to Week 68 and Successful Therapy Discontinuation in Patients with Non-Radiographic Axial Spondyloarthritis Who Achieved Sustained Remission on 28-Week Open-Label Adalimumab Treatment
Background/Purpose: Sustained remission is an important treatment goal in patients (pts) with non-radiographic axial SpA (nr-axSpA). Factors predicting successful remission maintenance are unknown. We sought…Abstract Number: 1507 • 2017 ACR/ARHP Annual Meeting
Comparison of the Clinical and Imaging Arms of the Assessment of Spondyloarthritis International Society Classification Criteria and Parameters of Objective Inflammation in Patients with Non-Radiographic Axial Spondyloarthritis
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) recommendations for use of TNF inhibitors (TNFi) in axial SpA include active disease and a positive expert opinion,…Abstract Number: 1513 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Background/Purpose: Timely identification of nr-axSpA may lead to earlier intervention to reduce symptoms, improve function, and reduce disease burden. The purpose of this study was…Abstract Number: 1515 • 2017 ACR/ARHP Annual Meeting
Improvements in Enthesitis Scores with Certolizumab Pegol Treatment in Males and Females with Active Axial Spondyloarthritis Are Maintained to Week 204
Background/Purpose: Axial spondyloarthritis (axSpA), characterized by spinal inflammation, is also associated with extra-spinal manifestations including inflammation of the entheses (enthesitis). Enthesitis is equally prevalent throughout…Abstract Number: 1566 • 2017 ACR/ARHP Annual Meeting
Elevated IL-1 Expression Levels in Mesenchymal Stem Cells Derived from Spondyloarthitis Patients Might be Linked to Increased Osteoblast Mineralization
Background/Purpose: Axial spondyloarthritis (AxSpA) is an immune–mediated inflammatory disease involving the spine and sacroiliac joint. AxSpA is characterized by vertebral trabecular bone loss and progressive…Abstract Number: 1573 • 2017 ACR/ARHP Annual Meeting
In Vivo Phosphorylation of p38 in Monocytes Is Enhanced in Patients with Axial Spondyloarthritis (axSpA) at the Time of Diagnosis
Background/Purpose: Host response to microbes is considered to contribute to the pathogenesis to axSpA and other HLA-B27 associated diseases. The p38 MAP kinase pathway plays…Abstract Number: 1787 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis
Background/Purpose: It is not known whether TNF blockers can be stopped in non-radiographic (nr-axSpA) patients who are in remission. In ABILITY-1, adalimumab (ADA) significantly improved…Abstract Number: 1831 • 2017 ACR/ARHP Annual Meeting
A Positive MRI of the Sacroiliac Joints Is Not Specific for Axial Spondyloarthritis but Frequently Occurs in Healthy Individuals
Background/Purpose: Inflammation shown on MRI of the sacroiliac joint (MRI-SI) is prevalent in axSpA (±30%) but the specificity is not well known, hence we compared…Abstract Number: 1877 • 2017 ACR/ARHP Annual Meeting
The Performance of MRI Using the 3D Volumetric Interpolated Breath-Hold Sequence (VIBE) Technique to Detect Structural Changes in Patients with Early Axial Spondyloarthritis in Comparison to Conventional Radiography and Computed Tomography
Background/Purpose: Magnetic resonance imaging (MRI) is the gold standard for detection of inflammation in the sacroiliac joints (SIJ) of patients (pts) with axial spondyloarthritis (axSpA),…Abstract Number: 2438 • 2017 ACR/ARHP Annual Meeting
Open Label Transitioning from Originator Etanercept to Biosimilar SB4 Compared to Continuing Treatment with Originator Etanercept in a Historical Cohort in Rheumatic Diseases in Daily Practice
Background/Purpose: Blinded transitioning from originator infliximab (INX) to biosimilar CT-P13 was not inferior to continuing INX treatment.1 Open label mandatory transitioning resulted in a slightly…Abstract Number: 2500 • 2017 ACR/ARHP Annual Meeting
Are Work Outcomes Improved in Axial Spondyloarthritis (axSpA) Patients with Biologic Therapy? Results from the British Society for Rheumatology Register
Background/Purpose: Patients with axial spondyloarthritis (axSpA) identify the ability to stay at work as a priority. Biologic therapy improves disease activity and quality of life…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 16
- Next Page »